▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR ] Celltrion said on Dec. 2 that the European Medicines Agency has accepted its application for marketing authorization to a subcutaneous version of Remsima, its biosimilar of autoimmun...
[THE INVESTOR] Samsung BioLogics CEO Kim Tae-han reaffirmed key shareholders on Nov. 30 that the company’s accounting practice was legitimate, seeking a court injunction to nullify disciplinary acti...
[THE INVESTOR] Celltrion said on Nov. 29 it has obtained marketing authorization from the US Food and Drug Administration for Truxima, its copy version of Roche’s Rituxan (rituximab), to treat non-H...
[THE INVESTOR] Samsung BioLogics said on Nov. 28 it has filed an administrative lawsuit against a recent ruling by the country‘s financial regulator that the company violated accounting rules. T...
[THE INVESTOR] Korean display module firm Enerzent said on Nov. 22 it has signed an engineering, procurement and construction contract with US-based Micronoc for the design of energy consumption sol...
[THE INVESTOR] The growth of digital health care industry in Korea is being hindered by red tape in personal medical data and telemedicine sectors, a group of startups said on Nov. 22. The Asan Nan...
[THE INVESTOR] Celltrion refuted on Nov. 21 a news report that founder and Chairman Seo Jung-jin threw his weight around and abused a flight attendant last week. This follows a report by local cabl...
[THE INVESTOR] Korea’s iNtRon Biotechnology said on Nov. 20 it has clinched a deal with Switzerland-based Roivant Sciences to out-license SAL200, an investigational biologic for the treatment of inf...
[THE INVESTOR] Kolon Life Science said on Nov. 19 it has entered an agreement with Mundipharma to license out Invossa, its gene therapy designed to treat osteoarthritis, for the Japanese market, in ...
[THE INVESTOR] Korea’s leading biosimilar manufacturer Celltrion said on Nov. 19 that it has won approval from the US Food and Drug Administration for its tablet for treating HIV in the United State...
[THE INVESTOR] Bridge Biotherapeutics said on Nov. 19 it has filed an Investigational New Drug application with the US Food and Drug Administration to initiate phase 1 trials of BBT-877, a potent be...
[THE INVESTOR] Retail investors are estimated to hold more than 3 trillion won worth of Samsung BioLogics shares, whose trading was suspended last week over window-dressing, a corporate researcher s...
[THE INVESTOR] JW Pharmaceutical said on Nov. 16 it has received approval to initiate phase 2b clinical trials of URC102, its drug candidate to treat gout, from Korea’s Ministry of Food and Drug Saf...
[THE INVESTOR] Analysts here downplayed on Nov. 15 the potential delisting of Samsung BioLogics following a ruling by Korea’s financial regulator that the sixth-highest valued company on KOSPI is gu...
[THE INVESTOR] The trading of Samsung BioLogics shares was halted as Korea’s Financial Services Commission concluded on Nov. 14 that the contract drug manufacturer intentionally breached accounting ...
Cafe24 provides Vietnamese language service to online shopping platform operators
Why this Korean startup sees YouTube as its biggest competitor
Kakao Ventures invests in AI data platform
‘Blockchain, there’s no turning back’
Market Kurly founder reveals her fundraising secrets
Cafe24 unveils AI-powered online store management
S. Korea-Japan trade feud disrupts Samsung’s Galaxy Note production
Wengie’s agent says K-pop formula can boost global music industry
July 17, 2019
